Novel short-acting κ(kappa)-opioid receptor selective antagonists are translational tools to examine the impact of the κ-receptor/dynorphin system in assays related to central nervous system dysfunction (e.g., substance use disorders, anhedonia and depression). The effects of such compounds have been compared in males and females under very limited conditions.
Aims:
The goal of this study was to examine potential sex differences in the effects of a κ-agonist and a short-acting κ-antagonist in an ethologically relevant test of anhedonia, the “splash test” of self-grooming, and also in the forced swim test and in locomotor activity.
Methods:
We examined the dose-dependence of grooming deficits caused by the κ-agonist U50,488 (0.1–3.2 mg/kg intraperitoneal (i.p.)) in gonadally intact adult male and female C57BL/6J mice. We then compared the effects of the short-acting κ-antagonist LY2795050 ((3-chloro-4-(4-(((2S)-2-pyridin-3-ylpyrrolidin-1-yl)methyl) phenoxy)benzamide)); 0.032–0.1 mg/kg i.p.) in blocking grooming deficits caused by U50,488 (3.2 mg/kg). The effects of LY2795050 were also studied in the forced swim test (FST). The effects of LY2795050 in blocking the locomotor depressant effects of U50,488 (10 mg/kg) were also studied.
Results:
U50,488 produced dose-dependent grooming deficits in male and female mice, and LY2795050 prevented these effects. In contrast, LY2795050 decreased immobility in the FST in males at a dose of 0.1 mg/kg, but not in females, up to a dose of 0.32 mg/kg. Also, LY2795050 (0.32 mg/kg) prevented and also reversed the locomotor-depressant effects of U50,488 (10 mg/kg), in males and females.
Conclusions:
This study further implicates the κ-receptor system in ethologically relevant aspects of anhedonia, and confirms sexual dimorphism in some behavioral effects of novel κ-antagonists.
AbrahamADSchattauerSSReichardKL, et al. (2018) Estrogen regulation of GRK2 inactivates kappa opioid receptor signaling mediating analgesia, but not aversion. J Neurosci38: 8031–8043.
2.
BangasserDAWicksB (2017) Sex-specific mechanisms for responding to stress. J Neurosci Res95: 75–82.
3.
BeardsleyPMHowardJLSheltonKL, et al. (2005) Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats. Psychopharmacology (Berl)183: 118–126.
4.
BeckerJBChartoffE (2019) Sex differences in neural mechanisms mediating reward and addiction. Neuropsychopharmacology44: 166–183.
5.
BielajewCKonkleATKentnerAC, et al. (2003) Strain and gender specific effects in the forced swim test: Effects of previous stress exposure. Stress6: 269–280.
6.
Bolea-AlamanacBBaileySJLovickTA, et al. (2018) Female psychopharmacology matters! Towards a sex-specific psychopharmacology. J Psychopharmacol32: 125–133.
7.
BroadbearJHNegusSSButelmanER, et al. (1994) Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on kappa-opioid agonists in the mouse writhing assay. Psychopharmacology (Berl)115: 311–319.
8.
BrowneCAEricksonRLBlendyJA, et al. (2017) Genetic variation in the behavioral effects of buprenorphine in female mice derived from a murine model of the OPRM1 A118G polymorphism. Neuropharmacology. 117: 401–407.
9.
BrowneCAFalconERobinsonSA, et al. (2018) Reversal of stress-induced social interaction deficits by buprenorphine. Int J Neuropsychopharmacol21: 164–174.
10.
BurgessPMHarrisMGCoombsT, et al. (2017) A systematic review of clinician-rated instruments to assess adults’ levels of functioning in specialised public sector mental health services. Aust NZ J Psychiatry51: 338–354.
11.
ButelmanERCaspersMLovellKM, et al. (2012) Behavioral effects and central nervous system levels of the broadly available kappa-agonist hallucinogen salvinorin A are affected by P-glycoprotein modulationin vivo. J Pharmacol Exp Ther341: 802–808.
12.
ButelmanERMcElroyBDPrisinzanoTE, et al. (2019) Impact of pharmacological manipulation of the k-opioid receptor system on self-grooming and anhedonic-like behaviors in mice. J Pharmacol Exp Ther370: 1–8.
13.
CarlezonWAJrBeguinCDiNieriJA, et al. (2006) Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther316: 440–447.
14.
Castagne’VMoserPRouxS, et al. (2011) Rodent models of depression: Forced swim and tail suspension behavioral despair tests in rats and mice. Curr Protoc Neurosci Chapter 8: Unit 8.10A.
15.
ChangCByonWLuY, et al. (2011) Quantitative PK-PD model-based translational pharmacology of a novel kappa opioid receptor antagonist between rats and humans. AAPS J13: 565–575.
16.
ChavkinCCohenJHLandBB (2019) Repeated administration of norbinaltorphimine produces cumulative kappa opioid receptor inactivation. Front Pharmacol10: 88.
17.
ConwaySMPuttickDRussellS, et al. (2019) Females are less sensitive than males to the motivational- and dopamine-suppressing effects of kappa opioid receptor activation. Neuropharmacology146: 231–241.
18.
CraftRMBernalSA (2001) Sex differences in opioid antinociception: Kappa and ‘mixed action’ agonists. Drug Alcohol Depend63: 215–228.
19.
de LaatBGoldbergAShiJ, et al. (2019) The kappa opioid receptor is associated with naltrexone-induced reduction of drinking and craving. Biol Psychiatry. 86: 864–871.
20.
DiesterCMBanksMLNeighGN, et al. (2019) Experimental design and analysis for consideration of sex as a biological variable. Neuropsychopharmacology44: 2159–2162.
21.
EndohTMatsuuraHTanakaC, et al. (1992) Nor-binaltorphimine: A potent and selective kappa-opioid receptor antagonist with long-lasting activityin vivo. Arch Int Pharmacodyn Ther316: 30–42.
22.
FaunceKEBanksML (2019) Effects of repeated kappa-opioid receptor agonist U-50488 treatment and subsequent termination on intracranial self-stimulation in male and female rats. Exp Clin Psychopharmacol. 28: 44–54.
23.
ForresterSYJahanN (2020) Depression onset in long-term adolescent cannabinoid use: A neurobiological review. Cureus12: e7759.
24.
FriedEIEpskampSNesseRM, et al. (2016) What are ‘good’ depression symptoms? Comparing the centrality of DSM and non-DSM symptoms of depression in a network analysis. J Affect Disord189: 314–320.
25.
GerhardGSKaniperSPayntonB (2019) Fentanyl overdoses and pharmacogenetics. Pharmacogenet Genomics. 30: 5–8.
26.
GhasemiAZahediaslS (2012) Normality tests for statistical analysis: A guide for non-statisticians. Int J Endocrinol Metab10: 486–489.
27.
GuerreroMUrbanoMKimE-K, et al. (2019a) Design and synthesis of a novel and selective kappa opioid receptor (KOR) antagonist (BTRX-335140). J Med Chem62: 1761–1780.
28.
Haj-MirzaianANikbakhshRRamezanzadehK, et al. (2019) Involvement of opioid system in behavioral despair induced by social isolation stress in mice. Biomed Pharmacother109: 938–944.
29.
HoranPTaylorJYamamuraHI, et al. (1992) Extremely long-lasting antagonistic actions of nor-binaltorphimine (nor-BNI) in the mouse tail-flick test. J Pharmacol Exp Ther260: 1237–1243.
30.
JacobsonMLBrowneCALuckiI (2020a) Kappa opioid receptor antagonists as potential therapeutics for stress-related disorders. Annu Rev Pharmacol Toxicol60: 615–636.
31.
JacobsonMLWulfHATsudaMC, et al. (2020b) Sex differences in the modulation of mouse nest building behavior by kappa opioid receptor signaling. Neuropharmacology177: 108254.
32.
JonesJDBabalonisSMarcusR, et al. (2019) A randomized, double-blind, placebo-controlled study of the kappa opioid receptor antagonist, CERC-501, in a human laboratory model of smoking behavior. Addict Biol25: e12799.
33.
KalueffAVStewartAMSongC, et al. (2016) Neurobiology of rodent self-grooming and its value for translational neuroscience. Nat Rev Neurosci17: 45–59.
34.
KendlerKS (2016) The phenomenology of major depression and the representativeness and nature of DSM criteria. Am J Psychiatry173: 771–780.
35.
KoMCJohnsonMDButelmanER, et al. (1999) Intracisternal nor-binaltorphimine distinguishes central and peripheral kappa-opioid antinociception in rhesus monkeys. J Pharmacol Exp Ther291: 1113–1120.
36.
KrystalADPizzagalliDASmoskiM, et al. (2020) A randomized proof-of-mechanism trial applying the ‘fast-fail’ approach to evaluating κ-opioid antagonism as a treatment for anhedonia. Nat Med26: 760–768.
37.
Laman-MahargAWilliamsAVZufeltMD, et al. (2018) Sex differences in the effects of a kappa opioid receptor antagonist in the forced swim test. Front Pharmacol9: 93.
38.
LiuJJChiuYTDiMattioKM, et al. (2019) Phosphoproteomic approach for agonist-specific signaling in mouse brains: mTOR pathway is involved in kappa opioid aversion. Neuropsychopharmacology44: 939–949.
39.
LoweSLWongCJWitcherJ, et al. (2014) Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects. J Clin Pharmacol54: 968–978.
40.
MaLXuYJiangW, et al. (2019) Sex differences in antidepressant effect of sertraline in transgenic mouse models. Front Cell Neurosci13: 24.
41.
MassalyNCopitsBAWilson-PoeAR, et al. (2019) Pain-induced negative affect is mediated via recruitment of the nucleus accumbens kappa opioid system. Neuron102: 564–573.e6.
42.
McRaeAF (2017) Analysis of genome-wide association data. In: JMKeith (ed.) Bioinformatics: Volume II: Structure, Function, and Applications. New York: Springer, pp.161–173.
43.
MeliefEJMiyatakeMCarrollFI, et al. (2011) Duration of action of a broad range of selective kappa opioid receptor antagonists is positively correlated with c-Jun N-terminal kinase-1 activation. Mol Pharmacol80: 920–929.
44.
MettenPSchlumbohmJPHuangLC, et al. (2017) An alcohol withdrawal test battery measuring multiple behavioral symptoms in mice. Alcohol68: 19–35.
45.
NaganawaMDickinsonGLZhengMQ, et al. (2015a) Receptor occupancy of the kappa opioid antagonist LY2456302 measured with PET and the novel radiotracer 11C-LY2795050. J Pharmacol Exp Ther356: 260–266.
46.
NaganawaMZhengMQHenryS, et al. (2015b) Test-retest reproducibility of binding parameters in humans with 11C-LY2795050, an antagonist PET radiotracer for the kappa opioid receptor. J Nucl Med56: 243–248.
47.
NaganawaMZhengMQNabulsiN, et al. (2014) Kinetic modeling of (11)C-LY2795050, a novel antagonist radiotracer for PET imaging of the kappa opioid receptor in humans. J Cereb Blood Flow Metab34: 1818–1825.
48.
NegreteRGarcia GutierrezMSManzanaresJ, et al. (2016) Involvement of the dynorphin/KOR system on the nociceptive, emotional and cognitive manifestations of joint pain in mice. Neuropharmacology116: 315–327.
49.
NegusSSMelloNK (1999) Opioid antinociception in ovariectomized monkeys: comparison with antinociception in males and effects of estradiol replacement. J Pharmacol Exp Ther290: 1132–1140.
50.
NegusSSO’ConnellRMorrisseyE, et al. (2012) Effects of peripherally restricted kappa opioid receptor agonists on pain-related stimulation and depression of behavior in rats. J Pharmacol Exp Ther340: 501–509.
51.
NemethCLPaineTARittinerJE, et al. (2010) Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats. Psychopharmacology (Berl) 210: 263–274.
52.
Paschen-WolffMMCampbellANCTrossS, et al. (2019) DSM-5 substance use disorder symptom clusters and HIV antiretroviral therapy (ART) adherence. AIDS Care32: 645–650.
53.
PlaczekMSSchroederFACheT, et al. (2018) Discrepancies in kappa opioid agonist binding revealed through PET imaging. ACS Chem Neurosci10: 384–395.
54.
PleilJD (2016) QQ-plots for assessing distributions of biomarker measurements and generating defensible summary statistics. J Breath Res10: 035001.
55.
PorsoltRDBertinAJalfreM (1978) “Behavioural despair” in rats and mice: Strain differences and the effects of imipramine. Eur J Pharmacol51: 291–294.
56.
PortoghesePSLipkowskiAWTakemoriAE (1987) Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists. Life Sci40: 1287–1292.
57.
ReedBButelmanERFryR, et al. (2017) Repeated administration of opra kappa (LY2456302), a novel, short-acting, selective KOP-r antagonist, in persons with and without cocaine dependence. Neuropsychopharmacology43: 739–750.
58.
ReedBFangNMayer-BlackwellB, et al. (2012) Chromatin alterations in response to forced swimming underlie increased prodynorphin transcription. Neuroscience220: 109–118.
59.
Rorick-KehnLMWitkinJMStatnickMA, et al. (2014) LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. Neuropharmacology77: 131–144.
60.
RussellSERachlinABSmithKL, et al. (2014) Sex differences in sensitivity to the depressive-like effects of the kappa opioid receptor agonist U-50488 in rats. Biol Psychiatry76: 213–222.
61.
SeneyMLSibilleE (2014) Sex differences in mood disorders: perspectives from humans and rodent models. Biol Sex Differ5: 17.
62.
SensJSchneiderEMauchJ, et al. (2017) Lipopolysaccharide administration induces sex-dependent behavioural and serotonergic neurochemical signatures in mice. Pharmacol Biochem Behav153: 168–181.
63.
ShiotaNNarikiyoKMasudaA, et al. (2016) Water spray-induced grooming is negatively correlated with depressive behavior in the forced swimming test in rats. J Physiol Sci66: 265–273.
64.
ShirayamaYIshidaHIwataM, et al. (2004) Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects. J Neurochem90: 1258–1268.
65.
SmithMAGreene-NaplesJLLyleMA, et al. (2009) The effects of repeated opioid administration on locomotor activity: I. Opposing actions of mu and kappa receptors. J Pharmacol Exp Ther330: 468–475.
66.
SorgeREMartinLJIsbesterKA, et al. (2014) Olfactory exposure to males, including men, causes stress and related analgesia in rodents. Nature Methods11: 629–632.
67.
SpanagelRAlmeidaOFXShippenbergTS (1994) Evidence that nor-binaltorphimine can function as an antagonist at multiple opioid receptor subtypes. Eur J Pharmacol264: 157–162.
68.
UnterwaldEMRubenfeldJMKreekMJ (1994) Repeated cocaine administration upregulates kappa and mu, but not delta, opioid receptors. Neuroreport5: 1613–1616.
69.
VijayAWangSWorhunskyP, et al. (2016) PET imaging reveals sex differences in kappa opioid receptor availability in humans, in vivo. Am J Nucl Med Mol Imaging6: 205–214.
70.
WalshSLStrainECAbreuME, et al. (2001) Enadoline, a selective kappa opioid agonist: Comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berl)157: 151–162.
71.
WangYJRasakhamKHuangP, et al. (2011) Sex difference in kappa-opioid receptor (KOPR)-mediated behaviors, brain region KOPR level and KOPR-mediated guanosine 5′-O-(3-[35S]thiotriphosphate) binding in the guinea pig. J Pharmacol Exp Ther339: 438–450.
72.
YalcinIBelzungCSurgetA (2008) Mouse strain differences in the unpredictable chronic mild stress: A four-antidepressant survey. Behav Brain Res193: 140–143.
73.
ZhangHShiYGWoodsJH, et al. (2007) Central kappa-opioid receptor-mediated antidepressant-like effects of nor-Binaltorphimine: Behavioral and BDNF mRNA expression studies. Eur J Pharmacol570: 89–96.
74.
ZhangYButelmanERSchlussmanSD, et al. (2005) Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: Agonist actions at kappa opioid receptors. Psychopharmacology (Berl)179: 551–558.
75.
ZhengMQNabulsiNKimSJ, et al. (2013) Synthesis and evaluation of 11C-LY2795050 as a kappa-opioid receptor antagonist radiotracer for PET imaging. J Nucl Med54: 455–463.
